Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03588637
NCT03588637CompletedNot Applicable

Real-world Effectiveness and Safety on Daptomycin in Gram-Positive Infections in Chinese Intensive Care Units

West China Hospital1 site in 1 country200 target enrollmentStarted: June 1, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
200
Locations
1
Primary Endpoint
mortality
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Analyze the effectiveness and safety of Daptomycin(Jiangsu Hengrui Medicine Co., Ltd) in Gram-positive infections in Chinese Intensive Care Units by using the real-world data platform, https://rws.scccmqc.com. Patients who received at least one dose of Daptomycin between 2016 to 2021 are eligible.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Other

Eligibility Criteria

Ages
1 Year to 100 Years (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patient who received at least one dose of daptomycin

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

mortality

Time Frame: 30 days

death

Cure Rate

Time Frame: 30 days

clinical and microbiological effectiveness

Secondary Outcomes

  • Number of participants with treatment-related adverse events(30 days)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Xuelian Liao

Principal Investigator

West China Hospital

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 3
Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. AureusBacterial EndocarditisBacteremia
NCT00093067Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Unknown
Phase 2
Daptomycin With Rifampin for Treatment of Staphylococcal Prosthetic Joint InfectionStaphylococcal Infections
NCT01144000Andrej Trampuz60
Completed
Phase 3
China Registration Study in Patients With Skin InfectionsSkin DiseasesInfectious
NCT00772447AstraZeneca265
Completed
Phase 4
Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)Bacteremia
NCT01728376Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)82
Unknown
Not Applicable
Population Pharmacokinetic Analysis of Daptomycin in Patients With Osteoarticular InfectionsBone InfectionJoint Infection
NCT03134521Hospices Civils de Lyon189